Ibiden (4062.T) — 2027Q1 FY2027 Earnings Call Analysis

41% Raise, Almost All Price

Volume contributed JPY 3 billion to a JPY 37 billion operating profit raise. Every other yuan came from ASP and mix.

Thesis: Ibiden owns the substrate bottleneck for AI GPU and switching IC packages and is extracting real pricing from it. The entire FY26 beat is price and mix against flat volume because every plant is at capacity. The trade works while the shortage runs, but the ASP comp normalizes when Cell 6/8 land in FY2028 and competitor capacity arrives, and the next substrate generation (EMIB-T) is unproven at yield with mass production still 18 months out.

Verdict: HOLD — Conviction: MEDIUM

Catalyst: FY2027 capex decision before end of current fiscal year. If management commits to Cell 7/9 or acquired buildings, it confirms structural demand beyond this cycle. If they delay, the shortage thesis is narrower.

Key Risk: FY2027 ASP roll-off. The 26.5B gain is largely a flattened price-down curve and cost pass-through. When the curve steepens again post-competition, the year-over-year comp reverses against a fully-utilized plant with no volume lever.

The Tell: Miyazaki volunteered: 'We are happy if we can double the ASP, but that could be very challenging realistically. This is not only us that can determine the ASP.' He undercut the single largest driver of his own 41% raise unprompted, revealing that pricing leverage is negotiated, not structural.

Detected Patterns

Beat and Raise Machine: Operating profit raised 41% from JPY 90B to JPY 127B, net profit from 63B to 84B, first-half alone up 43%. Backed by specific waterfall with ASP/mix at 26.5B and sourcing secured for revised plan.
Pricing Power Signal: Price-down curve flattened or eliminated since May 11 across GPU, CPU, switching IC, PC. Not customer-specific: 26.5B spread across multiple accounts. Customers accepting increases because substrate supply is industry-wide shortage.
Capital Conviction: JPY 500B committed to Cell 6/8 with 50% equipment orders placed. Capex decision timeline accelerated from 'this or next fiscal year' to 'before end of current fiscal year.' Buying additional buildings on the table.
Capacity Ceiling: Volume adds only 3B of 37B raise. Management states almost everything except Intel Cell 5 is at full capacity and 'difficult to expect huge contributions' from volume. New capacity starts FY2027, contributes nothing until FY2028.
High Utilization as Ceiling: Full utilization presented as demand strength, but locks the volume lever. Growth is entirely price-dependent while the company races to add supply on a two-year lag.
Backlog Quality: No cancellable backlog disclosure, no book-to-bill, no inventory aging. 'Demand exceeding industry supply capacity' is a market claim, not a contracted number. Cannot verify backlog durability.
Generation-Skipping Execution Risk: EMIB-T yield undisclosed ('improved quite a lot'), shipment timing 'still fluid,' mass production at Gama not until 2028. Next substrate generation pushed past the current cycle with no quantified progress.

Friction Level: MODERATE_FRICTION — Facts align: full capacity, real shortage, price-driven beat. Disagreement is on whether flattened price-down curves and structural substrate shortage persist after Cell 6/8 and competitor capacity land in FY2028, or whether FY2027 ASP comps collapse against this year's elevated baseline.

Report not found

The report data is no longer available. Please return to the archive.

41% Raise, Almost All Price | Silicon Signal